Clinical trial

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-07-01

PhaseEARLY_PHASE1

Study timeline

Study start (unknown)2015-07-01Date precision: month

Registry last updated2022-01-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cognitive Dysfunctionunresolved

Interventions

DHADRUG

PlaceboDRUG

Sponsors & collaborators

Carol Fabian, MDlead sponsor

dsm-firmenich Switzerland AGcollaborator

Mapped research locations

Kansas CityKansas, United States1 DecaturIllinois, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02517502 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.